Lasa Supergenerics Ltd Slides to Record Low Amid Prolonged Downtrend

Price Action and Market Performance

On 05 Oct 2026, Lasa Supergenerics Ltd underperformed the broader market, falling 4.76% while the Sensex gained 0.67%. This drop extended the stock’s year-to-date loss to 42.37%, significantly worse than the Sensex’s 15.05% decline over the same period. The stock’s 3-month and 1-month performances are equally sobering, with losses of 28.00% and 20.00% respectively, compared to the Sensex’s more modest declines of 6.90% and 5.39%. Over the last five years, the stock has shed 93.00% of its value, starkly contrasting with the Sensex’s 21.17% gain. what is driving such persistent weakness in Lasa Supergenerics when the broader market is in rally mode?

Technical Indicators Signal Continued Pressure

The technical landscape for Lasa Supergenerics Ltd remains challenging. The stock trades below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring the prevailing downtrend. The overall technical trend is mildly bearish as of 29 Sep 2026, following a prior bearish phase. Weekly indicators such as MACD and Bollinger Bands are bearish, while monthly signals show a mixed picture with mild bullishness in MACD and KST. Immediate support rests at the 52-week low of Rs. 5.39, with resistance levels at Rs. 6.22 (20 DMA) and Rs. 7.22 (100 DMA). Delivery volumes have shown some volatility, with a 48.26% increase in 1-day delivery compared to the 5-day average, though overall volumes remain subdued. does the technical setup suggest any near-term relief or further downside risk?

Valuation Metrics Reflect Elevated Risk

The valuation profile of Lasa Supergenerics Ltd is complex and points to heightened risk. The company is loss-making, with a trailing twelve months (TTM) price-to-earnings ratio not applicable due to negative earnings. The price-to-book value ratio stands at a low 0.57x, indicating the stock trades below its book value. Enterprise value multiples are negative for EBITDA (-4.55x) and EBIT (-2.63x), reflecting the company’s negative earnings before interest, taxes, depreciation, and amortisation. The EV/Sales ratio is elevated at 5.89x, suggesting the market values the company at nearly six times its sales despite losses. Dividend yield is nil, with the last dividend paid in September 2022. The stock’s current price is 56.66% below its 52-week high of Rs. 12.46. should you be looking at Lasa Supergenerics as a potential entry point or is there more downside ahead?

Financial Performance and Profitability Challenges

The financials of Lasa Supergenerics Ltd reveal a company struggling to generate profits. Over the past year, profits have declined by a staggering 525.1%, with the company reporting a negative EBITDA of Rs. -8.24 crores. The average EBIT to interest coverage ratio is a weak -5.95x, indicating difficulties in servicing debt obligations. Return on equity (ROE) is negligible at 0.06%, signalling minimal profitability relative to shareholders’ funds. The company’s operating losses contribute to a weak long-term fundamental strength, with a 5-year sales growth contraction of 48.97% and a 5-year EBIT decline of 190.34%. Despite low leverage, with an average net debt to equity ratio of 0.18, the financial trend remains flat as of June 2026. how sustainable is the current financial trajectory for Lasa Supergenerics?

Quality Metrics and Shareholding Structure

The quality assessment of Lasa Supergenerics Ltd is below average, reflecting the company’s ongoing struggles. Management risk and growth metrics are both rated below average, while capital structure is considered good due to low leverage. Institutional holdings are negligible at 0.0%, and promoter shareholding remains the majority stake, with 20.66% of shares pledged. The company’s average return on capital employed (ROCE) is negative at -0.70%, further underscoring operational difficulties. Tax ratio is low at 1.76%, and dividend payout is zero, consistent with the loss-making status. does the shareholding pattern provide any clues about confidence levels among insiders?

Key Data at a Glance

Summary and Outlook

The trajectory of Lasa Supergenerics Ltd is marked by a persistent decline in share price, compounded by weak financial results and subdued technical indicators. The stock’s valuation metrics reflect the challenges faced by the company, with negative earnings and depressed multiples. While the company maintains low leverage, profitability remains elusive, and the quality metrics suggest limited growth prospects. The absence of institutional investors and the presence of pledged shares add layers of complexity to the ownership structure. Should you buy, sell, or hold at these levels? Explore the complete multi-factor analysis of Lasa Supergenerics Ltd to find out what the data signals at this all-time low.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →